Logo

Bayer Initiates P-III Study of Aflibercept for the Prevention of Blindness in Premature Infants with Retinopathy of Prematurity

Share this

Bayer Initiates P-III Study of Aflibercept for the Prevention of Blindness in Premature Infants with Retinopathy of Prematurity

Shots:

  • The P-III study will assess the efficacy- safety and tolerability of Aflibercept (intravitreal) in ~100 infants with ROP across 34 countries
  • Bayer & Regeneron collaborated to develop aflibercept whereas Regeneron holds exclusive rights to aflibercept in the US while Bayer retained exclusive marketing rights outside the US with equal profit sharing (Ex-Japan)
  • Aflibercept (marketed as Eylea) is an anti-VEGF therapy approved in ~100 countries for 5 indications including patients with wAMD- macula edema following retinal vein occlusion- diabetic macular edema and myopic choroidal neovascularization

Ref: Bayer | Image: All Work

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions